Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Search

Page Path

HOME
Search

Letter to the Editor

Functional cure of chronic hepatitis B encounters resmetirom

Nai-Bin Yang, Wai-Kay Seto, Ming-Hua Zheng

Clin Mol Hepatol. 2024;30(3):580-581. Published online April 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0301

View: 1751 Download: 89

Original Article

Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy

Qi Wang, Qingfa Bu, Zibo Xu, Yuan Liang, Jinren Zhou, Yufeng Pan, Haoming Zhou, Ling Lu

Clin Mol Hepatol. 2024;30(3):515-538. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0107

View: 2629 Download: 236

Review

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 3701 Download: 210 Web of Science: 10 Crossref: 14

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Yi-wen Shi, Jian-Gao Fan

Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0401

View: 4056 Download: 111

Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0318

View: 4383 Download: 190 Web of Science: 11 Crossref: 13

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 7973 Download: 528 Web of Science: 54 Crossref: 58

Editorial

Adding to the confusion in more than just the name

Jacob George

Clin Mol Hepatol. 2023;29(4):973-976. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0367

View: 1992 Download: 74 Web of Science: 6 Crossref: 6

Correspondence

Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(3):817-819. Published online May 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0155

View: 2242 Download: 48

Original Article

Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis

Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim

Clin Mol Hepatol. 2023;29(3):693-704. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2022.0330

View: 3726 Download: 185 Web of Science: 8 Crossref: 8

Editorial

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?

Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang

Clin Mol Hepatol. 2023;29(2):404-407. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0069

View: 3179 Download: 81 Web of Science: 2 Crossref: 2

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Kee-Huat Chuah, Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(2):401-403. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0062

View: 2988 Download: 70 Web of Science: 3 Crossref: 3

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2023;29(2):377-380. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0061

View: 2913 Download: 101 Web of Science: 2 Crossref: 1

Review

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

View: 10868 Download: 699 Web of Science: 55 Crossref: 56

Snapshot

Personalized medicine in nonalcoholic fatty liver disease

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):935-938. Published online June 24, 2022

DOI: https://doi.org/10.3350/cmh.2022.0175

View: 4739 Download: 147 Web of Science: 7 Crossref: 6

Editorial

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):806-809. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0208

View: 2746 Download: 72

Review

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):790-801. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0070

View: 7761 Download: 508 Web of Science: 45 Crossref: 46

Editorial

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease

Seonghwan Hwang, Won Kim

Clin Mol Hepatol. 2022;28(3):478-480. Published online June 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0143

View: 3413 Download: 92

Original Article

Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis

Gang Xu, Yu-Min Wang, Miao-Miao Ying, Sui-Dan Chen, Zong-Rui Li, Hong-Lei Ma, Ming-Hua Zheng, Jian Wu, Chunming Ding

Clin Mol Hepatol. 2021;27(2):329-345. Published online January 20, 2021

DOI: https://doi.org/10.3350/cmh.2020.0261

View: 7559 Download: 233 Web of Science: 14 Crossref: 16

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases

Yun Seok Kim, Sang Geon Kim

Clin Mol Hepatol. 2020;26(4):715-727. Published online September 22, 2020

DOI: https://doi.org/10.3350/cmh.2020.0173

View: 10053 Download: 277 Web of Science: 33 Crossref: 34

Review

Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2020;26(4):461-475. Published online September 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0136

View: 8995 Download: 289 Web of Science: 40 Crossref: 40

Editorial

Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?

Ju Hyun Shim

Clin Mol Hepatol. 2020;26(2):183-184. Published online March 12, 2020

DOI: https://doi.org/10.3350/cmh.2020.0042

View: 4573 Download: 115 Web of Science: 6 Crossref: 6

Review

Recent research trends and updates on nonalcoholic fatty liver disease

Jeong-Ju Yoo, Won Kim, Moon Young Kim, Dae Won Jun, Sang Gyune Kim, Jong-Eun Yeon, Jin Woo Lee, Yong Kyun Cho, Sang Hoon Park, Joo Hyun Sohn

Clin Mol Hepatol. 2019;25(1):1-11. Published online August 8, 2018

DOI: https://doi.org/10.3350/cmh.2018.0037

View: 19285 Download: 721 Web of Science: 70 Crossref: 66

Original Article

Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis

Wataru Ando, Hiroaki Yokomori, Nobuhiro Tsutsui, Eigoro Yamanouchi, Yutaka Suzuki, Masaya Oda, Yutaka Inagaki, Katsuya Otori, Isao Okazaki

Clin Mol Hepatol. 2018;24(1):61-76. Published online November 20, 2017

DOI: https://doi.org/10.3350/cmh.2017.0030

View: 9765 Download: 178 Web of Science: 30 Crossref: 30

Review

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs

Stephen Caldwell

Clin Mol Hepatol. 2017;23(2):103-108. Published online May 10, 2017

DOI: https://doi.org/10.3350/cmh.2017.0103

View: 12795 Download: 482 Web of Science: 33 Crossref: 33

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2013;19(4):325-348. Published online December 28, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.4.325

View: 14091 Download: 164 Crossref: 95

Editorial

Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis

Goh Eun Chung, Donghee Kim

Clin Mol Hepatol. 2013;19(2):116-119. Published online June 27, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.2.116

View: 7143 Download: 93

Case Report

Severe steatohepatitis with hepatic decompensation resulting from malnutrition after pancreaticoduodenectomy

Eun Hui Sim, Jung Hyun Kwon, Se Young Kim, Seung Min Jung, Lee-So Maeng, Jeong Won Jang, Kyu Won Chung

Clin Mol Hepatol. 2012;18(4):404-410. Published online December 21, 2012

DOI: https://doi.org/10.3350/cmh.2012.18.4.404

View: 7729 Download: 86 Crossref: 16

3

Validity and reliability of the nonalcoholic fatty Liver diseases activity score (NAS) in Korean NAFLD patients and its correlation with clinical factors

Kyung-Hun Lee, M.D., Sang Hoon Park, M.D., Yu Jin Kim, M.D., Kyung Rim Huh, M.D., Kwang Seon Min M.D., Sun-Young Jun M.D., Kyoung Oh Kim, M.D., Cheol Hee Park, M.D., Taeho Hahn, M.D., Kyo-Sang Yoo, M.D., Jong Hyeok Kim, M.D., Myung-Seok Lee, M.D., Choong Kee Park, M.D.

Clin Mol Hepatol. 2010;16(1):29-37. Published online March 26, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.1.29

PDF

View: 5286 Download: 56 Crossref: 2

Current status of Liver diseases in Korea: nonalcoholic fatty Liver disease

Sang Hoon Park

Clin Mol Hepatol. 2009;15(60):34-39. Published online December 31, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.S6.S34

PDF

View: 7337 Download: 45 Crossref: 19

2

Pathology of nonalcoholic steatohepatitis

Yoon Mi Jeen , So Young Jin

Clin Mol Hepatol. 2009;15(2):122-130. Published online June 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.2.122

PDF

View: 5224 Download: 57 Crossref: 3

1 | 2 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

14.0
First decision

07 Days

Publication after acceptance

03 Days

*Last 12 months

MOST VIEWED MOST CITED

MOST VIEWED (Last 6 months)

Viewed By 4951	MAFLD: How is it different from NAFLD?
Viewed By 4831	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4741	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4455	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4413	Global incidence and prevalence of nonalcoholic fatty liver disease

MOST CITED (2022-2024)

Cited By 214	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 117	MAFLD: How is it different from NAFLD?
Cited By 95	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051 FAX: +82-2-703-0071 E-mail: kasl@kams.or.kr

Copyright © The Korean Association for the Study of the Liver.

COUNTER

TODAY : 1276

TOTAL : 2090596